睿知中国疾病研究地图
候选清单0

正在招募血友病 AIII期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

ClinicalTrials.gov 上登记的一项血友病 A开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京儿童医院Beijing Children's Hospital北京医院页面
  2. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
  3. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05611801,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 2

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(2 项)收起清单
  1. 1 岁 至 17 岁;性别:仅男性

    登记记录的入选字段

  2. Known HIV-positive for participants aged 1 to 5 years of age

    排除标准第 6 条

    CD4 cell count ≤200/uL if HIV-positive, for participants aged 6 to 17 years

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05611801,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male participants of appropriate age and required minimum weight
  2. Participants aged 12 to 17 years must be at least 25 kgs at time of consent.
  3. Participants aged 6 to 11 years must be at least 19 kgs at time of consent.
  4. Participants aged 1 to 5 years must be at least 5 kgs at time of consent.
  5. Participants with a diagnosis of severe hemophilia A or moderately severe to severe hemophilia B
  6. Participants must have at least 1 year (if aged 6 to 17 years), or at least 3 months (if aged 1 to 5 years) of diary and/or medical records available in which exogenous FVIII or FIX replacement or bypass agent infusions and hemophilic bleeding episodes were consistently documented over over the above specified timeframe to the time of consent.
  7. No current detectable inhibitor and no documented history of inhibitors in the 5 years prior to consent
  8. Must have at least 50 exposure days to FVIII/FIX replacement products for participants aged 6 to 17 years. Participants from 1 to 5 years do not require a minimum documented number of exposure days
  9. Must be at least 80% compliant with a stable and effective routine prophylaxis regimen with FVIII/FIX replacement products, for at least 12 months prior to consent for participants aged 6 to 17 years, for at least 3 months prior to consent for participants from 1 to 5 years
  10. Documentation of current high titer inhibitor (≥5 BU/mL); or current low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery <60% of expected within previous 12 months prior to the time of consent
  11. Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the high quantitative inhibitor criteria described in the prior bullet at the time of screening (eg, participant with a previously documented high-titer inhibitor ≥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement may be considered for eligibility on a case-by-case basis with discussion and agreement from the Pfizer medical monitor.
  12. Participants aged 6 to 17 years: Hemophilia A participants with on-demand treatment regimen with ≥12 bleeding episodes or hemophilia B participants with on-demand treatment regimen with ≥8 bleeding episodes (spontaneous or traumatic) necessitating treatment with bypass factor in the 12 months prior to informed consent
  13. Participants aged 1 to 5 years of age with at least 3 months' on-demand bypass treatment regimen and at least 1 treated hemophilic bleeding in the last 3 months or at least 2 treated hemophilic bleedings in the last 6 months documented prior to the time of informed consent
  14. Participants aged 6 to 17 years must be on an on-demand bypass treatment regimen during the 12 months prior to informed consent
  15. Participants aged 1 to 5 years of age must be on an on-demand bypass treatment regimen during the 3 months prior to informed consent

排除标准:Exclusion Criteria:

  1. Known coronary artery, thrombotic, or ischemic disease, or current evidence of congenital or acquired thrombophilic disease such as Anti-thrombin III deficiency, Factor V Leiden mutation, prothrombin 20210 mutation, protein C deficiency, protein S deficiency and antiphospholipid syndrome.
  2. Known planned surgical procedure during the planned study period
  3. Known hemostatic defect other than hemophilia A or B
  4. Abnormal hematology, renal or hepatic function laboratory results at screening
  5. Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice, or cirrhosis. Participants aged 1 to 5 years with known hepatitis B or C will also be excluded
  6. Known HIV-positive for participants aged 1 to 5 years of age
  7. Other acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator
  8. Individuals with known allergic reaction or hypersensitivity to hamster protein or other components of the study intervention
  9. Current routine prophylaxis with bypassing agent, non-coagulation non-factor replacement therapy (eg, emicizumab), or any previous treatment with a gene therapy product for treatment of hemophilia
  10. Participants with inhibitors who are being treated using a prophylaxis treatment regimen with a bypass agent, and, participants who have previously received non-factor-based hemophilia therapy (eg, fitusiran, concizumab, emicizumab) will be considered on a case-by-case basis, only after discussion and agreement between the investigator and the Pfizer medical monitor
  11. Regular use of immunomodulatory medications (eg, IVIG, routine systemic corticosteroids, rituximab)
  12. Use of systemic antifibrinolytics, medications that may increase the risk of bleeding, and certain non-steroidal anti-inflammatory drugs within 120 hours of first dose of study intervention and while on study. Some of these agents may be permitted if it is authorized for use in the respective country, is part of the standard of care in the study population, its use is short term and on a PRN basis and following discussion with the Pfizer medical monitor.
  13. Ongoing or planned use of ITI, or prophylaxis with FVIII or FIX replacement at any time after initiation of treatment with study intervention
  14. Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry or during study participation
  15. Previous exposure to marstacimab during participation in other marstacimab clinical studies
  16. CD4 cell count ≤200/uL if HIV-positive, for participants aged 6 to 17 years
  17. Abnormal ECG of clinical relevance that may affect participant safety or interpretation of study results
  18. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members

引自 ClinicalTrials.gov, NCT05611801, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05611801,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05611801